Oncocyte Q4 revenue $1.5M, GAAP loss $33.5M; transplant test on track for 2026 FDA authorization

Insight Molecular Diagnostics Inc.

Q4 2024 pharma-services revenue $1.5M; full-year $1.9M; gross margin 40%.
GAAP loss from continuing ops $33.5M ($1.93/sh); non-GAAP operating loss $4.4M.
Recorded $41.9M intangible impairment (DetermaCNI $35.1M, DetermaIO $6.8M) offset by $13.7M contingent consideration gain.
Cash $10.3M at year-end; raised $29.1M in Feb 2025 offering; Bio-Rad holds ~9.66% stake.
Targeting FDA submission for kitted transplant assay GraftAssureDx by end 2025; authorization expected 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.